Logo image of OMER

OMEROS CORP (OMER) Stock Fundamental Analysis

NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD

9.18  -0.43 (-4.47%)

After market: 9.18 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OMER. OMER was compared to 194 industry peers in the Pharmaceuticals industry. OMER may be in some trouble as it scores bad on both profitability and health. OMER does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OMER had negative earnings in the past year.
In the past year OMER has reported a negative cash flow from operations.
In multiple years OMER reported negative net income over the last 5 years.
OMER had negative operating cash flow in 4 of the past 5 years.
OMER Yearly Net Income VS EBIT VS OCF VS FCFOMER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

OMER's Return On Assets of -42.93% is in line compared to the rest of the industry. OMER outperforms 41.62% of its industry peers.
Industry RankSector Rank
ROA -42.93%
ROE N/A
ROIC N/A
ROA(3y)7.74%
ROA(5y)-22.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMER Yearly ROA, ROE, ROICOMER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMER Yearly Profit, Operating, Gross MarginsOMER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

OMER has less shares outstanding than it did 1 year ago.
OMER has more shares outstanding than it did 5 years ago.
OMER has a worse debt/assets ratio than last year.
OMER Yearly Shares OutstandingOMER Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
OMER Yearly Total Debt VS Total AssetsOMER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.65, we must say that OMER is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OMER (-4.65) is worse than 63.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACCN/A
OMER Yearly LT Debt VS Equity VS FCFOMER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

OMER has a Current Ratio of 2.96. This indicates that OMER is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.96, OMER perfoms like the industry average, outperforming 49.19% of the companies in the same industry.
A Quick Ratio of 2.96 indicates that OMER has no problem at all paying its short term obligations.
OMER has a Quick ratio (2.96) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
OMER Yearly Current Assets VS Current LiabilitesOMER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

OMER shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -821.88%.
EPS 1Y (TTM)-821.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OMER is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53%
EPS Next 2Y-5.38%
EPS Next 3Y26.07%
EPS Next 5Y42.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OMER Yearly Revenue VS EstimatesOMER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
OMER Yearly EPS VS EstimatesOMER Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OMER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMER Price Earnings VS Forward Price EarningsOMER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMER Per share dataOMER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

A more expensive valuation may be justified as OMER's earnings are expected to grow with 26.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.38%
EPS Next 3Y26.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OMER!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEROS CORP

NASDAQ:OMER (2/21/2025, 8:00:01 PM)

After market: 9.18 0 (0%)

9.18

-0.43 (-4.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners46.12%
Inst Owner Change-81.09%
Ins Owners4.42%
Ins Owner Change0%
Market Cap531.98M
Analysts80
Price Target40.29 (338.89%)
Short Float %16.91%
Short Ratio12.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.15%
Min EPS beat(2)16.34%
Max EPS beat(2)21.96%
EPS beat(4)3
Avg EPS beat(4)26.36%
Min EPS beat(4)-6.37%
Max EPS beat(4)73.5%
EPS beat(8)6
Avg EPS beat(8)71.14%
EPS beat(12)9
Avg EPS beat(12)55.89%
EPS beat(16)13
Avg EPS beat(16)46.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.14%
PT rev (3m)-8.14%
EPS NQ rev (1m)12.28%
EPS NQ rev (3m)12.28%
EPS NY rev (1m)3.09%
EPS NY rev (3m)6.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.31
EYN/A
EPS(NY)-2.09
Fwd EYN/A
FCF(TTM)-2.67
FCFYN/A
OCF(TTM)-2.67
OCFYN/A
SpS0
BVpS-2.66
TBVpS-2.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)7.74%
ROA(5y)-22.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -4.65
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)26.05%
Cap/Depr(5y)22.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-821.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y-53%
EPS Next 2Y-5.38%
EPS Next 3Y26.07%
EPS Next 5Y42.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.98%
OCF growth 3YN/A
OCF growth 5YN/A